Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 2Down Syndrome 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Plasmablastic Lymphoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Accelerated Phase 1HTLV-I Infections 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 30Rituximab 26Biopsy 23Specimen Handling 20Magnetic Resonance Spectroscopy 18fludarabine 14Prednisone 13Vincristine 11obinutuzumab 10Lenalidomide 10Etoposide 10Doxorubicin 10Bendamustine Hydrochloride 9pembrolizumab 7venetoclax 6fludarabine phosphate 6X-Rays 6Tacrolimus 6Nuclear Medicine Department, Hospital 6Dexamethasone 6Bortezomib 6trametinib 5ibrutinib 5glofitamab 5acalabrutinib 5Mycophenolic Acid 5Gemcitabine 5Crizotinib 5Busulfan 5copanlisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × prednylidene × 90 days × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡